MBX Biosciences, Inc. Common Stock Cash Flow Conversion Efficiency
MBX Biosciences, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, MBX Biosciences, Inc. Common Stock (MBX) has a cash flow conversion efficiency ratio of -0.046x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.21 Million) by net assets ($437.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MBX Biosciences, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of MBX Biosciences, Inc. Common Stock from 2022 to 2025. This chart illustrates how MBX Biosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MBX live share price for real-time trading data and today's change.
MBX Biosciences, Inc. Common Stock Cash Flow Conversion Ratio Explained
MBX Biosciences, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MBX Biosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MBX Biosciences, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see MBX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Engineers India Limited
NSE:ENGINERSIN
|
0.018x |
|
Semapa
LS:SEM
|
0.059x |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
0.000x |
|
Dynavax Technologies Corporation
NASDAQ:DVAX
|
0.063x |
|
Aerospace Industrial Development Corp
TW:2634
|
0.164x |
|
Viet Nam International Commercial Joint Stock Bank
VN:VIB
|
0.007x |
|
Xiangyang Changyuan Donggu Industry Co Ltd
SHG:603950
|
0.022x |
|
Alrov Properties & Lodgings Ltd
TA:ALRPR
|
0.006x |
Annual Cash Flow Conversion Efficiency for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of MBX Biosciences, Inc. Common Stock from 2022 to 2025. Review MBX Biosciences, Inc. Common Stock financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $369.22 Million | $-79.95 Million | -0.217x | -1.95% |
| 2024-12-31 | $257.44 Million | $-54.68 Million | -0.212x | -148.13% |
| 2023-12-31 | $-72.47 Million | $-31.98 Million | 0.441x | -18.69% |
| 2022-12-31 | $-42.60 Million | $-23.12 Million | 0.543x | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more